KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) EBITDA (2016 - 2025)

Historic EBITDA for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $1.9 billion.

  • AbbVie's EBITDA fell 5030.02% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 billion, marking a year-over-year decrease of 3458.98%. This contributed to the annual value of $9.1 billion for FY2024, which is 2837.66% down from last year.
  • AbbVie's EBITDA amounted to $1.9 billion in Q3 2025, which was down 5030.02% from $4.9 billion recorded in Q2 2025.
  • AbbVie's EBITDA's 5-year high stood at $5.5 billion during Q4 2022, with a 5-year trough of -$1.5 billion in Q4 2024.
  • Its 5-year average for EBITDA is $3.6 billion, with a median of $4.0 billion in 2024.
  • Per our database at Business Quant, AbbVie's EBITDA skyrocketed by 49055.85% in 2021 and then crashed by 14663.54% in 2024.
  • Quarter analysis of 5 years shows AbbVie's EBITDA stood at $5.1 billion in 2021, then increased by 8.44% to $5.5 billion in 2022, then plummeted by 41.93% to $3.2 billion in 2023, then plummeted by 146.64% to -$1.5 billion in 2024, then skyrocketed by 227.79% to $1.9 billion in 2025.
  • Its EBITDA was $1.9 billion in Q3 2025, compared to $4.9 billion in Q2 2025 and $3.7 billion in Q1 2025.